Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Advanz Agrees Multi-Market Omalizumab Deal With Alvotech
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

Lannett Eyes Another $11m In Savings With R&D Sea Change, Job Cuts
Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.

Henlius Kicks Off Trial For Darzalex Biosimilar
Shanghai Henlius Biotech has announced the start of Phase I trials for its HLX15 proposed daratumumab biosimilar rival to Darzalex. But the Chinese firm is not the only developer chasing the $8bn brand.

Sandoz Expects ‘Trough Year’ In 2023 As It Counts Cost Of Spinoff
Sandoz is set for a “trough year” in 2023 as the generics and biosimilars unit faces costs linked with its spinoff from parent company Novartis that will erode its core operating income.

Amgen Builds Up Future Launches As Oncology Biosimilars Slide
Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.

Kabi: US Pegfilgrastim Crowd Is An Opportunity For Us, Not A Deterrent
In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.

Fresenius Kabi And Formycon Ally On Stelara Rival
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.

Adalimumab Expectations Revised In The Wake Of Amgen Launch
The launch of Amgen’s Amjevita, the first US biosimilar rival to Humira, has been accompanied by multiple fresh forecasts of how competition could play out this year, with a host of further biosimilar launches on the horizon.

Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership
Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.